XML 88 R22.htm IDEA: XBRL DOCUMENT
v3.20.1

Reduction in Workforce | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2020 | Dec. 31, 2019
Restructuring and Related Activities [Abstract] |  |
Reduction in Workforce | 13. Reduction in Workforce In December 2019, the Company’s Board of Directors approved a restructuring plan to reduce operating costs and better align the Company’s workforce with its business needs following the Company’s November 2019 announcement regarding that top line data from the PROTECTOR 1 Phase 3 study, evaluating the safety and efficacy of RTB101 in preventing clinically symptomatic respiratory illness in adults age 65 and older, did not meet its primary endpoint, and that the Company has stopped the development of RTB101 in this indication. Under the restructuring plan, the Company reduced its workforce by 8 employees (approximately 22% of total employees). Affected employees are eligible to receive severance payments and outplacement services in connection with the reduction. In January 2020, the Company further reduced its workforce by 2 employees. During the quarter ended March 31, 2020, the Company recorded additional restructuring charges of approximately $0.1 million related to severance payments and other employee-related costs. During the quarter ended March 31, 2020, $0.5 million of the estimated restructuring charges were paid. The following table shows the total amount expected to be incurred and the liability related to the 2019 restructuring as of March 31, 2020:
|  | One-time Employee Termination Benefits |
|  | (In thousands) |
Accrued restructuring costs beginning balance |  | $ | 516 |
Restructuring charges incurred during the year |  |  | 112 |
Amounts paid during the year |  |  | (532 | )
Accrued restructuring costs as of March 31, 2020 |  | $ | 96 |
The Company expects the remaining accrued restructuring costs of $96,000 will be paid within the next 12 months. No other restricting costs are expected to be incurred. The following table summarizes the restructuring charges reported in the consolidated statements of operations and comprehensive loss for the quarter ended March 31, 2020:
|  | Cash |  |  | Non-cash |  |  | Total Expenses |
|  | (In thousands) |
Research and development |  | $ | 112 |  |  | $ | — |  |  | $ | 112 |
General and administrative |  |  | — |  |  |  | — |  |  |  | — |
Total |  | $ | 112 |  |  | $ | — |  |  | $ | 112 |
| 15. Reduction in Workforce In December 2019, the Company’s Board of Directors approved a restructuring plan to reduce operating costs and better align the Company’s workforce with its business needs following the Company’s November 2019 announcement regarding that top line data from the PROTECTOR 1 Phase 3 study, evaluating the safety and efficacy of RTB101 in preventing clinically symptomatic respiratory illness in adults age 65 and older, did not meet its primary endpoint, and that the Company has stopped the development of RTB101 in this indication. Under the restructuring plan, the Company reduced its workforce by 8 employees (approximately 22% of total employees). Affected employees are eligible to receive severance payments and outplacement services in connection with the reduction. During the year ended December 31, 2019, the Company recorded aggregate restructuring charges of approximately $0.6 million related to severance payments and other employee-related costs. The Company does not expect to incur any additional significant costs associated with this restructuring. During the year ended December 31, 2019, $66,000 of the estimated restructuring charges were paid. The Company expects the remaining accrued restructuring costs of $0.5 million will be paid in the next 12 months. The following table shows the total amount expected to be incurred and the liability related to the 2019 restructuring as of December 31, 2019:
|  | One-time Employee Termination Benefits |
|  | (In thousands) |
Accrued restructuring costs beginning balance |  | $ | — |
Restructuring charges incurred during the year |  |  | 582 |
Amounts paid during the year |  |  | (66 | )
Accrued restructuring costs as of December 31, 2019 |  | $ | 516 |
The following table summarizes the restructuring charges reported in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2019:
|  | Cash |  |  | Non-cash |  |  | Total Expenses |
|  | (In thousands) |
Research and development |  | $ | 306 |  |  | $ | — |  |  | $ | 306 |
General and administrative |  |  | 276 |  |  |  | — |  |  |  | 276 |
Total |  | $ | 582 |  |  | $ | — |  |  | $ | 582 |

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -URI http://asc.fasb.org/topic&trid=2175745 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration